1x1 Meetings with Stern IR Clients in SF – January 8-11, 2018

Stern IR will be scheduling and hosting meetings for many of our clients around the 2018 J.P. Morgan Healthcare Conference, being held January 8-11th in San Francisco.

This year we’ll be coordinating schedules for around 40 of our top-tier companies, listed here below with brief descriptions. To request specific meetings, please select those companies and fill out the short contact information form with your availability, and a member of our team will follow up shortly for scheduling.

Many of our companies will be hosting meetings in Stern IR suites at The Marker Hotel (501 Geary Street, b/t Jones & Taylor), just 2 blocks away from the conference location at the Westin St. Francis. See you in SF!

Need further assistance?

For any assistance or to schedule over the phone, please contact:

Phone: 212-362-1200
Email: [email protected]

Companies Hosting Meetings

Registration Form

Contact Information

Meeting Time Preferences

Please let us know what dates and times (PT) are best for you. If you are waiting for the 1x1 schedule, please check the box below.

Companies I'm Interested In

Check all that apply.

  • market cap ~$800M

    + more - less

    Pivotal-stage biotech developing eptinezumab, a monoclonal antibody inhibiting CGRP via quarterly infusion with top-line data from PROMISE 2 study in chronic migraine expected in 1H18. In the PROMISE 1 study in frequent episodic migraine, eptinezumab delivered preventative benefit on day 1 post-infusion, migraine prevention for 3 months post initial dose, high rates of patients with 50%-100% reductions in migraine days, deepening efficacy after a second dose at 3 months and safety/tolerability similar to placebo.

  • + more - less

    Privately-held company developing innovative therapies to treat age-related diseases, with an emphasis on cognitive dysfunction and neurodegeneration. The Company’s lead clinical candidate is a proprietary plasma-derived product that has been demonstrated to enhance cognition in preclinical studies and is well tolerated in humans. The product is in clinical development to treat mild-moderate Alzheimer’s Disease.

  • market cap ~$220M

    + more - less

    Specialty pharmaceutical company developing first-in-class, oral enzymes to treat patients with rare and severe metabolic and kidney disorders that result in the excess accumulation of certain metabolites, potentially causing kidney stones, damaging the kidney, and, in some cases, leading to CKD and ESRD. Pipeline includes two product candidates: ALLN-177, expected to enter pivotal Phase 3 studies in enteric hyperoxaluria in 1Q18, and ALLN-346, in preclinical development for hyperuricemia in patients with renal impairment. In November 2017, closed $75M initial public offering.

  • market cap ~$45M

    + more - less

    Irish specialty pharmaceutical company focused on the development of innovative new treatments to help improve the lives of patients with rare and orphan diseases, recently raised $17M in a private placement in the EU. The Company’s lead product, Episalvan, received marketing approval for the treatment of partial-thickness wounds from the European Commission in January 2016 and is currently being developed for the treatment of Epidermolysis Bullosa. A Phase 3 trial was initiated in April 2017 and a pre-specified interim analysis expected in early 2018.

  • + more - less

    Leading the field of targeted protein degradation with its proprietary PROTAC platform licensed from Yale University to induce elimination of pathological proteins. The company’s pipeline consists of the androgen receptor program targeting castration resistant prostate cancer and estrogen receptor program targeting ER+ breast cancer, both set to enter the clinic in 2018; and other programs in undruggable targets, oncology and CNS. Arvinas has established discovery platform deals with Genentech and Merck.

  • market cap ~$550M

    + more - less

    Raised $115M in Nasdaq IPO in May 2017; developing a pipeline of differentiated antibody-based therapies utilizing SIMPLE Antibody™ Platform. FcRn antagonist ARGX-113 is currently in Phase 2 studies in three severe autoimmune indications all with readouts in 2018, including myasthenia gravis (MG), immune thrombocytopenia (ITP), and pemphigus vulgaris (PV). Oncology candidate ARGX-110 targets CD70 and is currently in a Phase 2 trial in CTCL (monotherapy) and a Phase 1/2 trial (combination therapy) in AML and MDS patients, topline data expected in 2018. Innovative Access Program designed to further expand pipeline through strategic collaborations with academic centers and biotech companies including AbbVie, Leo Pharma, and Shire.

  • market cap ~$150M

    + more - less

    Biotherapeutics company engaged in the discovery and development of immunology-based therapeutics, harnessing human Physiocrine proteins, to treat patients suffering from rare immune-mediated diseases. Three pipeline candidates include iMod.Fc program for interstitial lung disease with an immune component, entering clinic by YE17; ORCA program for immuno-oncology, antibody IND-candidate selection by YE17; opportunistically pursuing partnerships for Resolaris program for rare muscular dystrophies with an immune component.

  • market cap ~$51M

    + more - less

    Specialty pharmaceutical company focused on the development and commercialization of IV tramadol for moderate to moderately severe postoperative pain. If successful, IV Tramadol would be the only intravenous Schedule IV opioid in the U.S. IV Tramadol fits into and facilitates the trend to minimize usage of conventional narcotics in the post-surgical setting. Tramadol is a synthetic dual-acting opioid with a well-established efficacy and safety profile, and oral tramadol is currently approved and marketed in the U.S. for moderate to moderately severe pain in adults. Currently evaluating IV Tramadol in pivotal Phase 3 trial in patients undergoing bunionectomy, with topline data expected in 2Q18; expect to initiate a second pivotal Phase 3 trial in patients undergoing abdominoplasty in 3Q18, with topline data expected as early as 2Q19.

  • + more - less

    BERG (Private): BERG is a clinical-stage company disrupting and re-defining the approach to drug discovery, research and development through its Interrogative Biology® platform, which identifies therapies and biomarkers by applying algorithm- and probability-based artificial intelligence to analyze large numbers of patients’ genotypic, phenotypic, lifestyle and demographic characteristics. BERG has leveraged its Interrogative Biology® platform to develop a robust pipeline of therapeutic product candidates including BPM31510, in Phase 1 and Phase 2 clinical trials for various oncology indications, and BPM31543, in a Phase 1 clinical trial for the treatment of chemotherapy-induced alopecia.

  • market cap ~$250M

    + more - less

    Leveraging proprietary platform technologies to discover and develop a deep pipeline of novel drug candidates targeting ion channels. Lead candidate, BNC210, is a modulator of α7 nicotinic acetylcholine receptor in development for the treatment of anxiety and depression. Bionomics reported positive Phase 2 data in GAD and is currently conducting a Phase 2 trial in PTSD with data anticipated in 2H18. The Company also has two clinical stage oncology assets positioned for monetization.

  • market cap ~$50M

    + more - less

    Leveraging its proprietary DNAbilize™ antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs that can be administered with a simple intravenous transfusion. Lead product candidate prexigebersen (BP1001), targeting the Grb2 protein, is in a Phase II study for blood cancers and in preclinical studies for solid tumors; second product candidate BP1002, targeting the Bcl2 protein, will be evaluated in lymphoma and solid tumors when it moves into the clinic.

  • market cap ~$1.8B

    + more - less

    Global leader in the custom development and manufacture of small molecule active pharmaceutical ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals, with long-standing customer relationships and a history of regulatory excellence. Net revenue and EBITDA for 2017 expected to increase 7-11% and 11-15% over 2016, respectively, representing the company’s seventh consecutive year of growth.

  • market cap ~$400M

    + more - less

    Clinical-stage biotech focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by targeting peripheral kappa opioid receptors (KORs). Lead candidate I.V. CR845 is a first-in-class KOR agonist that has demonstrated statistically significant reductions in itch scores and improvement in QoL measures in Phase 2 trials in hemodialysis patients with moderate-to-severe CKD-associated pruritus (CKD-aP). The Phase 3 IV program in CKD-aP in hemodialysis patients is expected to commence in 4Q17 and a Phase 1 trial with Oral CR845 in CKD-aP non-hemodialysis patients is also planned for 4Q17. The enrollment for the company’s ongoing Phase 3 trial in acute postoperative pain is expected to be complete in 4Q17. The company also plans to file an IND for chronic liver disease-associated pruritus (CLD-aP) with oral CR845 this year.

  • market cap ~$600M

    + more - less

    Clinical-stage company focused on the discovery and development of differentiated CAR-T therapies targeting the NKG2D ligand. Lead candidate CYAD-01 is currently in the Phase 1b THINK trial, evaluating safety and clinical activity without pre-conditioning chemotherapy in seven various solid and hemathological tumor types in the U.S. and Belgium. To-date in the dose-escalation portion of the THINK trial, a complete response (MLFS) was reported in an AML patient and other signals of clinical activity were reported in AML, CRC and ovarian patients.

  • market cap ~$300M

    + more - less

    Biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage compounds. In addition, Chimerix has in early-stage development a new clinical candidate, CMX521, for the treatment and prevention of norovirus.

  • + more - less

    Developing novel tumor-targeted and immuno-oncology therapies based on pioneering research in cancer epigenetics. Lead candidates include EZH2-inhibitor CPI-1205, expected to initiate a Phase 1b/2 trial in castration-resistant prostate cancer before YE17, and CPI-0610, a potential best-in-class BET inhibitor in Phase 2, enrolling additional patients in a molecularly-defined subset of NHL patients. Next generation EZH2 franchise enables greater potency, more durable target engagement and enhanced pharmaceutical properties in expanded solid tumor opportunity, with first IND expected in 2018. Additional novel discovery efforts focused on the nexus of epigenetics and immuno-oncology. Backed by notable venture funds, including The Column Group, Third Rock Ventures, Venrock, SROne and Altitude Life Sciences.

  • market cap ~$20M

    + more - less

    Clinical-stage biotech company using proprietary artificial intelligence technology, CHEMSAS, to accelerate the discovery and development of novel drug therapies to treat cancer and other unmet medical needs. Lead compound COTI-2, targeting mutant forms of p53, is in Phase 1 clinical trial for gynecological malignancies and head and neck squamous cell carcinoma; exploratory and secondary endpoint data from gynecological arm expected by year-end and top-line readout from HNSCC arm expected in 2018. Second compound COTI-219, targeting mutant forms of KRAS, is undergoing IND-enabling studies, with a regulatory submission expected in 2018.

  • market cap ~$1.0B

    + more - less

    Leading genome editing company developing revolutionary CRISPR-based medicines to treat patients with genetic diseases by correcting their disease-causing genes. Lead candidate EDIT-101 is in pre-clinical development for the treatment of Leber Congenital Amaurosis 10, with an IND filing planned for mid-2018. EDIT-101 was granted Orphan Medicinal Product designation for the treatment of LCA10 by the EMA, and the Company initiated a natural history study to assess the course of the disease and to pilot potential clinical trial endpoints. Editas Medicine has entered into two strategic collaborations, including one with Allergan to develop innovative treatments for eye diseases, and one with Juno Therapeutics for the development of engineered T cells to treat cancer.

  • market cap ~$35M

    + more - less

    Advancing novel Targeted Protein Therapeutics (TPTs) for the treatment of cancer both as monotherapies and in combination with checkpoint inhibitors; TPTs are single protein molecules comprised of antibody-fragments genetically fused to toxin payloads that directly kill targeted cancer cells and induce immunogenic cell death (ICD). Phase 3 candidate Vicinium is being evaluated in non-muscle invasive bladder cancer (NMIBC), with topline data expected in mid-2018, and will also be evaluated at the National Cancer Institute (NCI) in NMIBC in combination with Astra Zeneca’s PD-L1 checkpoint inhibitor durvalumab.

  • market cap ~$250M

    + more - less

    Developing targeted therapies for cancer and companion imaging agents. Lead candidate 177Lu-PSMA-617 is a radioligand therapeutic (RLT) that targets the prostate-specific membrane antigen (PSMA), with a Phase 3 trial expected to initiate in 1H18. Data presented at ESMO showed a 57% PSA response rate (>50% reduction) and 71% interim response rate in soft tissue lesions (as measured by RECIST criteria) in 30 prostate cancer patients who had failed conventional therapies. Pipeline also includes Endocyte’s CAR-T cell bi-specific adaptor molecule platform being developed in collaboration with Seattle Children's Research Institute, with an IND filing expected in 2018.

  • market cap ~$220M

    + more - less

    A clinical-stage company dedicated to the development of next-generation cellular immunotherapies for cancer and immune disorders, including NK- and T-cell immuno-oncology product candidates derived from renewable engineered induced pluripotent stem cell (iPSC) lines. The Company is collaborating with top investigators, including Drs. Jeffrey Miller (iPSC-derived NK cells; University of Minnesota) and Michel Sadelain (iPSC-derived CAR-T cells; Memorial Sloan Kettering), to pioneer its off-the-shelf cell products for the treatment of liquid and solid tumors, and expects to move these products into first-in-human testing during 2018.  In addition, FATE is currently conducting three clinical trials of FATE-NK100, a first-in-class NK cell cancer immunotherapy, for the treatment of AML, ovarian cancer and advanced solid tumors in combination with monoclonal antibody therapy; and a Phase 2 clinical trial of ProTmune, a next-generation allogeneic graft for the prevention of acute GvHD, a severe life-threatening condition that affects thousands of patients each year with hematologic malignancies and rare genetic disorders that seek curative outcomes through hematopoietic cell transplantation.

  • + more - less

    A leader in cellular and immune therapies that leverages the use of stem cells and natural killer cells for the treatment of cancer and orphan genetic diseases. Lead product NiCord currently in Phase 3 trial as a bone marrow transplantation solution for blood cancer patients who do not have a fully matched family related donor. NiCord has been granted Breakthrough Therapy Designation by the FDA, and orphan drug designations from the FDA and EMA. Broader pipeline includes CordIn, in Phase 1/2 trials as a potential curative treatment for sickle cell and thalassemia, as well as a Natural Killer cell product in Phase 1.

  • market cap ~$41M

    + more - less

    Developing next generation neoantigen cancer vaccines to help cure cancer by leveraging superiority of ATLASTM T cell antigen identification platform, which recalls a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor, to identify vaccine neoantigens. Lead program, GEN-009, is an adjuvanted neoantigen peptide vaccine that is designed to direct a patient’s immune system to attack their tumor. Plans to initiate a Phase 1 trial for GEN-009 in a range of tumor types in the first half of 2018 and expects to report initial immunogenicity data in the first half of 2019.

  • market cap ~$120M

    + more - less

    Potentially transformative I-O approach with IPI-549, believed to be the only oral, selective PI3K-gamma inhibitor in clinical development. Currently in a Phase 1/1b clinical study as a monotherapy and in combination with Opdivo in approximately 200 patients with advanced solid tumors, with encouraging Phase 1 data reported to date and multiple data readouts anticipated throughout 2018.

  • market cap ~$2B

    + more - less

    Building a leading specialty focused business in progressive non-viral liver diseases. OCALIVA™ (OCA), the first new therapy for primary biliary cholangitis (PBC) in 20 years, continues to grow steadily. Significant upside from further OCA indications including nonalcoholic steatohepatitis (NASH), with data from the Phase 3 REGENERATE trial expected in 1H19.

  • market cap ~$520M

    + more - less

    Formerly Lion Biotechnologies, clinical-stage company developing novel cancer immunotherapies based on its tumor infiltrating lymphocyte (TIL) technology. The company has a robust pipeline and key manufacturing partnerships and collaborations throughout the U.S. and the EU. The company’s lead product candidate for metastatic melanoma, LN-144, is in Phase 2 with fast track designation and is exploring the company’s shorter Gen 2 manufacturing process in cohort 2. The company is also enrolling patients in two Phase trials for LN-145 in head and neck and cervical cancer.

  • + more - less

    iTeos has a pipeline focused on expanding the benefits of immunotherapy for cancer patients with 4 programs targeting hot and cold tumors: IDO1 in Phase 1 and A2A and TIGIT candidates, which will start Phase 1 in 2018. The company uses a unique platform to identify rational combinations of immunotherapies and novel targets and was founded in 2011 as a spinoff of the Ludwig Institute for Cancer Research and the de Duve Institute at the University of Louvain.

  • market cap ~$500M

    + more - less

    Clinical stage immunotherapy company developing targeted therapies that enable the immune system to attack tumors. Its robust Translational Science Platform takes a precision approach by characterizing immune cell make-up of human tumors, and identifying new targets and biomarkers. The lead product candidate, JTX-2011 is an agonist monoclonal antibody that targets ICOS, is currently in Phase 2. Preliminary efficacy data expected in 1H18 across several solid tumor types. Jounce’s robust discovery pipeline includes programs targeting additional adaptive immune cells such as B cells and T regulatory cells, as well as innate immune cells, such as macrophages, and non-immune cells such as stromal cells. In July 2016, the company entered into a global strategic collaboration with Celgene.

  • market cap ~$175M

    + more - less

    R&D-focused, clinical-stage biopharmaceutical company seeking to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers. Leveraging efficient, biomarker-driven platform across its deep research engine and three lead programs in clinical development – MM-121 in non-small cell lung cancer and metastatic breast cancer, MM-141 in metastatic pancreatic cancer, and MM-310 in solid tumors – each of which is expecting data in 2018, including randomized Phase 2 studies of MM-121 and MM-141.

  • market cap ~$450M

    + more - less

    Clinical-stage company developing a pipeline of highly targeted antibody drug conjugates (ADCs), based on its proprietary Dolaflexin® platform, with increased drug payload, improved tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Lead product candidate, XMT-1522, is in Phase I clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. Second product candidate, XMT-1536, is expected to enter clinical trials in early 2018.

  • market cap ~$1B

    + more - less

    Specializes in the detailed structural analysis of complex drugs. FDA-approved complex generics include Enoxaparin Sodium Injection (LOVENOX®) and Glatopa 20 mg (COPAXONE® 20 mg) with Glatopa 40 mg ANDA currently under review; several biosimilars in various stages of development with lead asset M923 (HUMIRA®) progressing toward a submission for marketing approval in 4Q17; and a portfolio of novel drugs for autoimmune indications, led by M281 (anti-FcRn) with Phase 1 data expected in 4Q17, and M230 (SIF3), which is expected to enter the clinic in 4Q17 with collaboration partner CSL.

  • market cap ~$1.5B

    + more - less

    Growing pipeline focused on precision cardiovascular medicine; developing therapies for heritable cardiomyopathies resulting from biomechanical defects in cardiac muscle contraction. Lead candidate, mavacamten, has orphan drug designation for obstructive hypertrophic cardiomyopathy (oHCM). Reported positive data from first cohort in Phase 2 PIONEER study in August showing statistically significant improvements in post-exercise peak LVOT gradient and peak VO2. More milestones ahead for mavacamten program, with a pivotal EXPLORER study in oHCM and a Phase 2 study in non-obstructive HCM both starting soon.  Second program, MYK-491 for dilated cardiomyopathy (DCM), advancing through Phase 1 development. Ongoing collaboration with Sanofi. Closed $133.8M financing in August 2017.

  • market cap ~$235M

    + more - less

    Commercial-stage pharma company that develops, manufactures and commercializes products using its proprietary drug-delivery technology. Neos currently has three FDA-approved branded products for ADHD: Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets, Cotempla XR-ODT™ (methylphenidate) extended-release orally disintegrating tablets, and Adzenys ER™ (amphetamine) extended-release oral suspension. They plan to expand their pipeline into GI and CNS.

  • market cap ~$50M

    + more - less

    Fertility company developing treatment options for women based on breakthrough discovery of EggPCSM cells -- immature egg cells found in the protective ovarian lining. Product portfolio includes OvaPrimeSM, in clinical development, designed to replenish egg reserve and OvaTureSM, in preclinical development, designed to eliminate hormones from IVF. The Company’s AUGMENTSM Treatment, designed to improve IVF success, is also available in select IVF clinics in Canada.

  • market cap ~$100M

    + more - less

    French-listed biopharma leading breakthrough in combination drug development using big data curation, genomics and rigorous experimental analysis to target orphan indications, including lead candidate PXT3003 for Charcot-Marie-Tooth Disease Type 1A, currently in a pivotal Phase 3 trial with top-line results expected in 2H18. Pharnext also leverages its platform to target common indications through partnerships with companies such as Tasly and Galapagos.

  • + more - less

    Pioneering new approach to treating neurodegenerative diseases based on proprietary GAIM technology, which enables the simultaneous targeting of multiple toxic misfolded proteins, including amyloid β, tau, α-synuclein and prions. Lead product candidate NPT088 is in Phase 1b trial for Alzheimer’s disease; successful completion of Phase 1b is expected to support Phase 2 and 3 programs in Alzheimer’s and Parkinson’s disease. Also developing next generation product candidate NPT189 for orphan peripheral amyloidoses, with IND application filing planned for 1H18.

  • market cap ~$620M

    + more - less

    Biopharmaceutical company developing and commercializing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening obesity. Lead product candidate, setmelanotide, is potent, first-in-class, MC4R agonist, which has the potential to serve as a replacement therapy for MC4 pathway deficiencies. Setmelanotide is in Phase 3 trials for POMC and LepR deficiency obesity and granted breakthrough therapy designation from the FDA for both indications; additional proof-of-concept studies are underway in Bardet-Biedl syndrome, Alstrom Syndrome, POMC Heterozygous and POMC Epigenetic disorders. In October 2017, closed $138M initial public offering.

  • market cap ~$2.5B

    + more - less

    Clinical-stage biopharmaceutical company with portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Data from Phase 3 brexanolone (SAGE-547) program for the treatment of postpartum depression is currently expected by the end of this year. SAGE-217 is in Phase 2 development in both mood and movement disorders, with four Phase 2 clinical programs underway.

  • + more - less

    Private biotech company focused on next-generation modulation of growth factor signaling. Through their novel platform of supracellular activation, they selectively target growth factors in the disease microenvironment, including in neuromuscular diseases, cancer, and fibrosis. Lead clinical candidate SRK-015 is a selective and local inhibitor of latent myostatin and is being developed as a treatment to improve muscle strength and motor function in patients with Spinal Muscular Atrophy (SMA), in combination and as a monotherapy. Ongoing collaboration with Janssen Biotech for TGFβ1 in immuno-oncology and raised $58M to date.

  • + more - less

    Leading, next generation healthcare company that is transforming drug discovery by building and deploying breakthrough scientific software using physics-based technologies and accurate computational assays, allowing for exploration of a much larger fraction of chemical space than traditional approaches, leading to dramatically reduced time to development, higher quality clinical drug candidates, and lower costs. The Company has co-founded several biotech companies, most notably Nimbus Therapeutics, using its computational chemistry platform to design drug candidates, including Nimbus’s ACC program that was recently acquired by Gilead for $1.2B.

  • + more - less

    Development-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, galinpepimut-S, is a cancer immunotherapeutic agent, licensed from Memorial Sloan Kettering Cancer Center, targeting the WT1 protein. Galinpepimut-S has potential as a monotherapy or in combination to address a broad spectrum of hematologic and solid tumor indications. Galinpepimut-S is Phase 3-ready for two indications, AML and malignant pleural mesotheliomia (MPM), and is also in development as a potential treatment for multiple myeloma and ovarian cancer (in the latter tumor type in combination with BMS’ nivolumab). In October 2017, Sellas entered into an agreement with a Merck subsidiary to conduct Phase 1/2 trial activity across five indications in combination with Merck’s PD1 inhibitor pembrolizumab. In August 2017, Sellas entered into a definitive merger agreement with Galena BioPharma. The merger is expected to close in December 2017, subject to Galena shareholder vote approval.

  • market cap ~$450M

    + more - less

    Microbiome company developing broad pipeline of novel Ecobiotic® medicines to treat disease by restoring the function of a dysbiotic or unhealthy microbiome. Lead Phase 3 product candidate SER-109 has Breakthrough and Orphan designation for multiply-recurrent C. difficile infection. Pipeline includes SER-287, which in a Phase 1b study demonstrated an improvement in clinical remission rate and endoscopic improvement in patients with ulcerative colitis, and SER-262 under evaluation in a Phase 1b trial for primary C. difficile infection. Seres has ongoing research collaborations in infectious diseases, metabolic diseases, and immune diseases, including immuno-oncology.

  • market cap ~$154M

    + more - less

    Spero is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections. The company’s most advanced product candidate, SPR994, is designed to be the first broad-spectrum oral carbapenem-class antibiotic to treat MDR bacterial infections; topline data expected from Phase 1 trial in mid-2018 with potential Phase 3 to start in 2H18 in complicated UTIs. Potentiator Platform is novel technology enabled to expand spectrum and potency of existing antibiotics against gram-negative bacteria; Phase 1b trial expected to start in 4Q17 and Phase 2 in 1H18. The company raised $77 million in an IPO this November.

  • + more - less

    Leader in mitochondrial medicine; focused on the development of novel therapeutics that restore the normal structure and function to dysfunctional mitochondria that underlie rare genetic diseases and common diseases of aging. Phase 3 study of lead candidate elamipretide expected to launch in 4Q17 in primary mitochondrial disease; recently received Orphan Drug Designation in this indication. Elamipretide is also being tested in rare disease indications including: a Phase 2/3 trial for Barth syndrome and Phase 2 trial for Leber’s Hereditary Optic Neuropathy; and in common diseases of aging including: three Phase 2 POC trials in heart failure and a Phase 1 study in dry AMD.

  • market cap ~$250M

    + more - less

    Synlogic is a clinical stage company, pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform. Synlogic’s initial pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as urea cycle disorders (UCD) and phenylketonuria (PKU) through its platform extends to the treatment of liver disease, inflammatory and immune disorders, and cancer. Lead candidate, SNYB1020, for urea cycle disorders (UCD) and hepatic encephalopathy (HE) is in Phase 1 trials. Second candidate, SYNB1618, for Phenylketonuria (PKU) was recently granted an orphan drug designation by the FDA and the Company plans to submit an IND in early 2018. Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD).

  • market cap ~$420M

    + more - less

    Pioneering the understanding of the regulatory genome to advance a new wave of medicines that control the expression of disease-driving genes. Proprietary platform systemically and efficiently analyzes this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically-defined patient populations. Initially focused on cancer, including immuno-oncology, as well as autoimmune and genetic diseases. Expect to report initial clinical data from Phase 2 trial of SY-1425, an oral, first-in-class, selective RARα agonist for genomically defined subsets of AML and MDS, in 4Q 2017, and preliminary data from Phase 1 clinical trial of SY-1365, a first-in-class selective CDK7 inhibitor for advanced solid tumors, in 2018.

  • market cap ~$70M

    + more - less

    U.K.-listed commercial-stage specialty pharma innovating in the $2-3B U.S. prescription cough/cold market with extended-release technology and an additional revenue stream from active partnering of a significant NCE pipeline. Tuzistra® XR, the only 12-hour codeine-based liquid cough product, and Moxatag®, the only approved once-daily amoxicillin, are on the market in the U.S., and Vernalis expects to have two additional cough/cold products during the 2018-2019 season, and to report on proof of concept for two additional products in 2017-2018.

  • + more - less

    Clinical-stage biopharma company focused on applying its novel Hierotope® platform to identify unique disease targets and to design and engineer precision antibody-based biological medicines against such targets that are not adequately addressed with conventional approaches. Recently announced collaboration with Vir Biotechnology to develop and commercialize 5 programs for infectious disease and closed a $46.7M Series C. Lead product candidate VIS410 is in a Phase 2a clinical trial in ambulatory patients with influenza A, with funding from BARDA, and top-line results are expected in early 2018 followed by the start of a Phase 2b in hospitalized patients with influenza A. VIS649, an antibody in development for the treatment of IgA nephropathy, is expected to enter the clinic in 2018.

  • market cap ~$100M

    + more - less

    Focused on medical technologies for women’s health and wellness with the Viveve® System , a clinically-proven CMRF technology that delivers the GENEVEVE™ treatment to generate new collagen and restore vaginal tissue; available in 58 countries worldwide with regulatory clearances for vaginal laxity and/or improvement in sexual function in 54 countries. IDE submitted to the FDA for a sexual function label expansion with data from that pivotal study expected in mid-2019 if approved. Strategic partnership with InControl Medical that expands U.S. product portfolio to healthcare providers with FDA-approved medical devices for the treatment of stress, urge, and mixed incontinence, in addition to products that improve pelvic floor strength.

  • market cap ~$1.1B

    + more - less

    Clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer using proprietary XmAb® technology. Currently, 11 candidates engineered with the XmAb technology are in clinical development internally and with partners. Internal pipeline includes XmAb®5871, in Phase 2 trials for IgG4-RD and SLE; XmAb®7195, in subcutaneous administration Phase 1b trial for asthma and allergic disease; and bispecifics XmAb®14045 in Phase 1 trial for AML, XmAb®13676 in Phase 1 trial for B-cell malignancies, XmAb®18087, in preclinical development for neuroendocrine tumors, and XmAb®20717 in preclinical development for multiple oncology indications. Expect to report topline data from Phase 2 trial of XmAb5871 in IgG4-RD and from subcutaneous administration Phase 1b trial of XmAb7195 by year-end.

Sending ...